Odisha issues guidelines for use and issue of Tocilizumab and other new drugs

Written By Sharon Mathew

On 20th May, 2021 the Government of Odisha issued a revised set of guidelines for the use and issue of Tocilizumab and other new drugs in COVID. Tocilizumbab may be considered when all of the below criteria are met:

  • Presence of sever disease (preferably within 24 to 48 hours of onset of severe disease/ ICU admission)

  • Significantly raised inflammatory markers (CRP &/or IL-6)

  • Not improving despite the use of steroids

  • No active bacterial/ fungal/ tubercular infection

Recommended single dose: 4 to 6mg/kg (400 mg in 60kg adult) in 100 ml NS over 1 hour.

Sharon Mathew
Previous

Odisha issues notification discontinuing plasma therapy
Next

Haryana releases guidelines for distribution of injection Amphotericin B